Peter E. Boyd - 09 Aug 2023 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Role
SVP, Information Technology, Human Resources and Communications
Signature
/s/ Lori Braender, as Attorney-In-Fact
Issuer symbol
AQST
Transactions as of
09 Aug 2023
Net transactions value
$0
Form type
4
Filing time
09 Aug 2023, 16:30:32 UTC
Previous filing
05 May 2023
Next filing
11 Mar 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AQST Performance Stock Units Award $0 +50,000 $0.000000 50,000 09 Aug 2023 Common Stock 50,000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each performance-based stock unit ("PSU") represents a contingent right to receive one share of the Company's Common Stock. The PSUs have a Performance Period beginning on the Grant Date and ending on May 5, 2026 and, to the extent earned, will vest 100% on that date, subject to the grantee's continued employment or other service with the Company from the Grant Date through the last day of the Performance Period. The number of shares of Common Stock that will be earned at the end of the Performance Period is subject to increase or decrease from 50% to up to 150%, based on the achievement of pre-established Performance Price metrics. The Performance Price for these PSUs is defined as the 30-day average of the closing price of the Company shares as reported on the Nasdaq Stock Market immediately prior to and including the last calendar day of the Performance Period.

Remarks:

SVP, Information Technology, Human Resources and Communications